ARTICLE SUMMARY:
A blood analysis start-up seeks to provide clinicians with an objective reference where it matters most.
Perosphere Technologies originally entered the medical space in 2011 as Perosphere Inc., a spin-off from Brown University where co-founder and CEO Sasha Bakhru, PhD, is an adjunct assistant professor of medical science. Perosphere Inc.’s goal was to develop and market a small-molecule reversal agent for direct oral anticoagulant (DOAC) drugs such as Xarelto and Eliquis, two of the most frequently prescribed medications in the world. In the event of a traumatic injury or an intracranial or GI hemorrhage, to stop bleeding the blood-thinning effects of DOACs must be reversed. Yet when patients are admitted to hospitals with these emergencies and physicians must intuit without reliable quantitative measurements whether or not DOACs are in the patients’ systems, data shows that their judgments are incorrect nearly 30% of the time.
